NPC1 and NPC2 are currently included in gene panels for infantile cholestatic disease [39], early onset ataxia (EOA) [27], dystonia [38], IEMs [37], organic psychosis, early-onset cognitive decline, hepatosplenomegaly, and developmental delay. This evidence concerns the gene NPC2 and Dystonia.